Goldman Sachs Maintains Sell on PTC Therapeutics, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi maintains a Sell rating on PTC Therapeutics (NASDAQ:PTCT) but raises the price target from $18 to $32.
May 28, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs analyst Paul Choi maintains a Sell rating on PTC Therapeutics but raises the price target from $18 to $32.
The Sell rating suggests a negative outlook, but the raised price target indicates some positive reassessment of the company's value. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100